Dr. Tyler Martin is an infectious disease physician who has been leading biotech teams an companies for nearly 30 years. He led the team at Chiron that developed FLUAD (now a Sequirus product), and led the team at Dynavax that developed HEPLISAV-B. He has also held leadership positions in gene therapy, gene editing, monoclonal antibody, and pharmaceutical companies. He joined Aeolian when the company was formed in 2022.
Speaking In
2:15 PM - 2:30 PM
Monday, June 5
